Group 1: Core Insights - The third China International Supply Chain Promotion Expo showcased the health industry with a focus on medical health, quality of life, and Chinese premium products, highlighting cutting-edge products and technologies in the health sector [1] - The expo emphasized the integration of digital and biological technologies, presenting a comprehensive health service chain from birth to elderly care [1] Group 2: Company Highlights - L'Oréal, as the only foreign exhibitor in the beauty industry, presented its consumer-centric smart supply chain and global opportunity connections, aiming to foster collaboration and innovation within the industry [2] - Medtronic showcased its five pillars of innovation in the medical field, including local manufacturing and global integration, with a focus on the "Lantern Left Bundle Branch Pacing" heart catheter as a key innovation [2] - Starbucks highlighted its sustainable supply chain network in the coffee industry, collaborating with a leading energy systems company to set a green development benchmark [3] Group 3: Collaborative Efforts - Sanofi demonstrated its end-to-end healthcare ecosystem in China, celebrating 30 years of local manufacturing and showcasing the entire process of flu vaccine production and distribution [4] - Strong interest was noted at the booth of the Wellbeing Group, which focused on innovations in the cotton industry and aimed to connect various stakeholders to promote a healthy cotton industry [4][5] - GE Healthcare emphasized its role in enhancing the resilience of China's high-end medical device supply chain through extensive collaboration with over a thousand suppliers [5] Group 4: Industry Trends - The expo highlighted a deep consensus among upstream and downstream enterprises on collaborative development within the health industry [4] - The concept of a "win-win chain" was reiterated by multiple industry leaders, emphasizing the importance of collaboration and co-creation for a sustainable health future [5]

Core Insights - Medtronic is transforming its strategy in China from being an "innovative technology exporter" to a "local ecosystem builder" by focusing on five interconnected chains: innovation integration, local manufacturing, value co-creation, intelligent services, and collaborative supply chain [1][3] Local Manufacturing - Medtronic has invested in local production capabilities, exemplified by the Mazor XC spinal surgery robot, which is a localized version of its global Mazor X series, showcasing China's ability to produce high-end medical devices [3][4] - The "Genesis Electric Stapler," developed entirely in China, was brought from research to mass production within a year and is now used in over 500 hospitals domestically and has been exported globally [4] Innovation Integration - The Lantern left bundle branch pacing catheter, developed through collaboration with Chinese clinicians, represents a significant innovation that will serve global markets, highlighting China's role in driving global medical advancements [5] - Medtronic's first localized product in neurointervention, the "Mei An Xin" coil, has been designed to meet the needs of Chinese patients and is already implanted in 28 provinces [5] Collaborative Ecosystem - Medtronic's "value co-creation chain" and "collaborative supply chain" strategies are evident in its partnerships, such as the RDN technology for hypertension treatment, which is set to be the first device approved in the U.S., EU, and China simultaneously [6] - The company has developed nearly 7,000 supply chain partners in China, with projected procurement of approximately 5 billion RMB in the fiscal year 2025, emphasizing local supplier integration [6][7] Intelligent Services - Medtronic is establishing a digital healthcare innovation base in Beijing, set to open by the end of 2025, focusing on remote management and intelligent follow-up solutions to enhance the healthcare ecosystem in China [8] - The company's long-term commitment to the Chinese market is reflected in its strategy to foster cooperation and shared progress in medical innovation [9]